Modulate Bio
Allston, US · Founded 2023 · Delaware corporation · 1 known investors
Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
BiotechDeep TechHealthtech
Founders & leadership
Modulate Bio was founded in 2023 by Dario Doller and Kevin Hodgetts.
Investors · 1
Reported raises · per SEC filings
Form D private placements$785.3K disclosed across 1 round · 2024
▶$785.3KraisedApr 2026 · 10 investors · BiotechnologyRule 506(b)
▶$785.3KraisedApr 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin HodgettsPromoter
- Dario DollerExecutive Officer, Director, Promoter
- Andrew ThomsonExecutive Officer, Director, Promoter
- Offering amount
- $1M
- Amount sold
- $785.3K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Liberate Bio8 shared keywordsLiberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.
Modulight8 shared keywordsModulight Biotherapeutics develops therapies for people with neurological disorders, aiming for fast-acting, precise treatments that reduce symptoms such as seizures, tremors, and persistent pain without side effects.
Emulatebio8 shared keywordsEmulate develops Organ-Chip technology, including 30+ organ models such as liver, brain, and other human tissue chips, used for human-based preclinical drug safety and toxicity testing. It serves pharmaceutical and biomedical researchers as a human-relevant alternative to animal testing, and works closely with the FDA including acceptance into the ISTAND pilot program.
Create7 shared keywordsCREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies. The company focuses on RNA therapeutics and immune engineering for cancer, autoimmune disease, and transplant rejection applications.
Modulari-T7 shared keywordsModulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.
Applied Therapeutics7 shared keywordsApplied Therapeutics is a biopharmaceutical company developing treatments for rare diseases, with a portfolio focused on Classical Galactosemia and CMT-SORD. Its lead investigational drug, govorestat, targets disease pathways such as galactitol and sorbitol reduction.
Talus Bio7 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Modulo Bio7 shared keywordsModulo is a drug discovery company developing therapies that reprogram microglia — the brain's immune cells — to treat neurological conditions. It combines stem cell engineering, neurobiology, multiomics, CRISPR, single-cell techniques, and machine learning to model the neuroimmune system and identify neuroprotective microglial behaviors.
Companies competing with Modulate Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Modulate Bio do?
- Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.
- Who founded Modulate Bio?
- Modulate Bio was founded by Dario Doller, Kevin Hodgetts in 2023.
- Who are Modulate Bio's investors?
- Modulate Bio's investors include Pillar VC.
- How much funding has Modulate Bio raised?
- Modulate Bio has disclosed $785.3K raised across 1 round.
- Where is Modulate Bio headquartered?
- Modulate Bio is headquartered in Allston, US.